Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma
Jennifer L. Crombie(Dana-Farber Cancer Institute), Gary Simmons(Virginia Commonwealth University Medical Center), Robert Redd(Harvard University), Alex F. Herrera(City of Hope), Caron A. Jacobson(Dana-Farber Cancer Institute), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Omar Castañeda Puglianini(Moffitt Cancer Center), Mazyar Shadman(University of Washington), Philippe Armand(Harvard University), Anna Saucier(Dana-Farber Cancer Institute), Victor A. Chow(Whipps Cross University Hospital), Kevin Tang(Baylor College of Medicine), Geoffrey Shouse(City Of Hope National Medical Center)
Cited by 36
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595